Start your Trading & Investing Journey with us
Join our channel for Daily Free Trades with Live analysis on Youtube, Trade Setup with Important Levels, and Important Stock Market Updates
Neochem Bio Solutions IPO Review - Issue Date, Price, GMP, Subscription, Allotment, Lot Size, and Details
Neochem Bio Solutions Limited is a specialty performance chemicals manufacturer offering 350+ customized formulations across polymers, surfactants, silicones, esters and bio-based sustainable solutions. The company earns revenue by supplying customized chemicals to textile, home & personal care, industrial cleaning, paper, paints, water treatment and construction industries. Its products serve as critical functional additives improving strength, finishing, processing efficiency and lifecycle performance of end-use products.
Neochem Bio Solutions ,an Book Built Issue, amounting to ₹44.97 Crore,consisting entirely an fresh issue of 0.46 crore shares of ₹44.97 Crore.The subscription period for the Neochem Bio Solutions IPO opens on December 02, 2025, and closes on December 04, 2025. The allotment is expected to be finalized on or about Friday, December 05, 2025., and the shares will be listed on the NSE SME with a tentative listing date set on or about Tuesday, December 09, 2025.
The Share Price Band of Neochem Bio Solutions IPO is set at ₹93 to ₹98 per equity share. The Market Capitalisation of the Neochem Bio Solutions at IPO price of ₹98 per equity share will be ₹
167.78 Crores. The lot size of the IPO is 1200 shares. Retail investors are required to invest a minimum of ₹
235,200, 2 lots ( 2400 shares), while the minimum investment for High-Net-Worth Individuals (HNIs) is
3 lots (
3600 shares), amounting to ₹
352,800.
Vivro Financial Services Private Limited are the book running lead manager of the Neochem Bio Solutions Ltd. while MUFG Intime India Private Limited is the registrar for the issue. The Market Maker of the company is Rikhav Securities Ltd.
Neochem Bio Solutions Limited IPO GMP Today
The Grey Market Premium of Neochem Bio Solutions IPO is expected to be ₹0 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.
Neochem Bio Solutions Limited IPO Live Subscription Status Today: Real-Time Update
As of 05:30 PM on 02 December, 2025, the Neochem Bio Solutions IPO live subscription status shows that the IPO subscribed 0.58 times on its First Day of subscription period. Check the Neochem Bio Solutions IPO Live Subscription Status Today at NSE.
Neochem Bio Solutions Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Neochem Bio Solutions IPO allotment date is 05 December 2025, Friday, Neochem Bio Solutions IPO Allotment will be out on 05 December 2025, Friday.and will be live on Registrar Website from the allotment date.
Check MUFG Intime India Private Limited IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Neochem Bio Solutions IPO from the dropdown list of IPOs
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.
Objectives of Neochem Bio Solutions Limited IPO
Neochem Bio Solutions to utilise the Net Proceeds towards the following objects:
1. ₹2,390.00 Lakh is required for Funding the long-term working capital requirements of the Company
2. ₹1,000.00 Lakh is required for Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by our Company
3. General Corporate Purposes.
Refer to Neochem Bio Solutions Limited RHP for more details about the Company.
Neochem Bio Solutions Limited Day Wise IPO GMP Trend
| GMP Date | Issue Price | Expected Listing Price | GMP | Last Updated |
|---|---|---|---|---|
| November 26, 2025 | ₹ 98 | ₹ 98 | ₹0(0.0%) | 27 November 2025; 05:44 PM |
Neochem Bio Solutions IPO Details
| Market Capitalization | ₹167.78 Cr. |
| IPO Date | December 02, 2025 to December 04, 2025 |
| Listing Date | December 09, 2025 |
| Face Value | ₹10 Per Share |
| Price Band | ₹93 to ₹98 per share |
| Issue Price | ₹98 per share |
| Employee Discount | NA |
| Lot Size | 1200 Equity Shares |
| Total Issue Size | 45,88,800 Equity Shares (aggregating to ₹44.97 Cr) |
| Fresh Issue | 45,88,800 Equity Shares (aggregating to ₹44.97 Cr) |
| Offer for Sale | NA |
| Issue Type | Book Built Issue |
| Listing At | NSE SME |
| Share holding pre issue | 1,25,31,953 |
| Share holding post issue | 1,71,20,753 |
| Rating | Avoid |
Neochem Bio Solutions IPO Anchor Investors Details
| Bid Date | December 01, 2025 |
| Shares Offered | 13,03,200 |
| Anchor Portion Size (In Cr.) | 12.77 |
| Anchor lock-in period end date for 50% shares (30 Days) | January 04, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | March 05, 2026 |
Neochem Bio Solutions IPO Timeline (Tentative Schedule)
| IPO Open Date | Tue, Dec 2, 2025 |
| IPO Close Date | Thu, Dec 4, 2025 |
| Basis of Allotment | Fri, Dec 5, 2025 |
| Initiation of Refunds | Mon, Dec 8, 2025 |
| Credit of Shares to Demat | Mon, Dec 8, 2025 |
| Listing Date | Tue, Dec 9, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Thu, Dec 4, 2025 |
Neochem Bio Solutions IPO Reservation
| Investor Category | Shares Offered | Reservation % |
|---|---|---|
| QIB Portion | 2,178,000 | Not less than 50% of the Net Offer |
| Non-Institutional Investor Portion | 653,400 | Not more than 15% of the Net Issue |
| Retail Shares Offered | 1,524,600 | Not more than 35% of the Net Offer |
| Market Maker Portion | 232,800 | - |
Neochem Bio Solutions IPO Promoter Holding
| Share Holding Pre Issue | 91.12% |
| Share Holding Post Issue | 66.70% |
Neochem Bio Solutions IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,400 | ₹235,200 |
| Retail (Max) | 2 | 2,400 | ₹235,200 |
| S-HNI (Min) | 3 | 3,600 | ₹352,800 |
| S-HNI (Max) | 8 | 9,600 | ₹940,800 |
| B-HNI (Min) | 9 | 10,800 | ₹1,058,400 |
Neochem Bio Solutions IPO Subscription Status
| Investor Category | Shares Offered | Shares Bid For | No of Times Subscribed | Last Upadeted |
|---|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 2,178,000 | 1,91,42,400 | 8.79x | 05 December 2025; 10:28 AM |
| Non Institutional Investors(NIIS) | 886,200 | 1,40,88,000 | 15.90x | 05 December 2025; 10:28 AM |
| Retail Individual Investors (RIIs) | 1,524,600 | 1,43,76,000 | 9.43x | 05 December 2025; 10:28 AM |
| Total | 4,588,800 | 4,76,06,400 | 10.37x | 05 December 2025; 10:29 AM |
About Neochem Bio Solutions Limited
Neochem Bio Solutions Limited is a specialty performance chemicals manufacturer offering 350+ customized formulations across polymers, surfactants, silicones, esters and bio-based sustainable solutions. The company earns revenue by supplying customized chemicals to textile, home & personal care, industrial cleaning, paper, paints, water treatment and construction industries. Its products serve as critical functional additives improving strength, finishing, processing efficiency and lifecycle performance of end-use products.
Key Clients & Manufacturing Facilities
The company serves diversified domestic and international clients across India, Bangladesh, Vietnam, Australia, Egypt, Turkey, Uzbekistan, South Korea and Canada. Repeat customers contributed 90.88% in FY25 and 99.05% in H1 FY26, indicating strong client stickiness. The company operates a single manufacturing facility at Moraiya, Ahmedabad with in-house R&D, product application lab, ZLD (Zero Liquid Discharge) infrastructure and ISO 9001/14001/45001 certifications, enabling sustainable and compliant production.
Product Portfolio & Order Book Position
Neochem’s portfolio spans performance polymers, surfactants, silicones, esters and bio-based alternatives. These products lie at the “process-critical chemical input” stage for customers, meaning they directly influence product quality, durability and processing lifecycle. The company caters to demand through short-cycle purchase orders rather than long-term contracts, with no firm order book due to industry structure. However, repeat business above 90% provides stable execution visibility.
Mergers, Capex & Future Expansion Plans
The company plans capacity expansion and process modernization, supported by strong cash flows and improved profitability (ROE 48.8% in FY25). Future plans include scaling sustainable chemistries, enhancing exports, expanding R&D capabilities, and optimizing manufacturing via energy-efficient and low-emission processes. The company will fund these plans through internal accruals, debt and IPO proceeds.
Employees & Bankers
As on September 30, 2025, our Company had 64 employees, The Banker to the Company is Axis Bank Limited.
MANAGEMENT & VISION
Neochem is led by Managing Director Swapnil R. Makati and Whole-time Director Hemangini S. Dathia, supported by a professional senior management team. The leadership aims to build India’s leading specialty performance chemical company with focus on green, bio-based and customized formulations. Their near-term vision includes strengthening export markets, expanding manufacturing capacity, accelerating automation and enhancing R&D.
Long-term targets include doubling product portfolio depth, achieving higher global certifications and becoming a preferred supplier for technical textiles, home & personal care and industrial solutions. Funding for capex will be arranged through IPO proceeds, internal accruals, and prudent long-term borrowing, supported by strong cash generation and improving ROCE (41.7% in FY25).
INDUSTRY OVERVIEW
The Indian specialty chemicals industry is growing at ~10–12% CAGR, driven by rising domestic demand, China-plus-one sourcing and expanding applications across textiles, home care, coatings, construction, and water treatment. The global specialty chemical industry is significantly larger, with growth expectations of 5–6% CAGR led by sustainability transitions and bio-based chemistries.
Within India, the performance chemicals segment is among the fastest-growing verticals, supported by strong export potential. Market leaders include Rossari Biotech, Aarti Industries, Atul, and Indian Emulsifiers. Neochem’s revenue grew at 32% CAGR over FY23–FY25, outperforming industry peers, indicating strong positioning in the sector.
RISK FACTORS
- High Dependence on Repeat Customers
Repeat customers contribute 90–99% of total revenue. Any decline in orders, change in procurement strategy, or financial stress of major clients can significantly affect revenue visibility and capacity utilization. - Geographical Concentration of Raw Material Procurement
Over 71% of raw materials are sourced from Gujarat (FY25). Any supply disruptions, regulatory actions, cost inflation or logistical issues in this region can directly affect production schedules and margins. - Absence of Long-term Customer Contracts
Sales are based on short-term purchase orders without volume commitments. This creates uncertainty in production planning, inventory management and pricing stability, impacting margins and operational efficiency. - Intense Competition
The specialty chemical industry is competitive with domestic and global manufacturers offering cost-effective products. Competitors with stronger technology, capacity, or pricing power can pressure margins and market share. - Contract Labour Dependency
With 72 contract labourers as of H1 FY26, any default by contractors in wage payments can expose the company to legal liabilities, financial penalties, and workforce disruption. - Delayed Statutory Compliances
The company has had delays in GST, PF, ESIC, and TDS filings in past years. Recurring delays may attract penalties and reflect gaps in internal compliance systems. - Working Capital Risks
Any delay in customer payments increases working capital requirements and can strain liquidity. Despite no major defaults, delays can reduce cash flows and impact profitability.
KEY STRENGTHS & OPPORTUNITIES
- Diversified Product Portfolio
With 350+ customized formulations across polymers, surfactants, silicones and esters, the company caters to multiple industries, reducing concentration risk and enabling cross-segment demand opportunities. - Strong R&D and Sustainable Chemistry Focus
The in-house lab develops high-performance, bio-based and eco-compliant chemicals, including plant-derived softeners and phosphate-free agents. Certifications like ZDHC Level 3 and GOTS 7.0 enhance credibility. - Robust Distribution Network
A network of 50+ domestic distributors and direct exports to over 12 countries helps the company scale volumes efficiently while increasing brand visibility in global markets. - High Growth & Improving Financial Metrics
Revenue CAGR of 32%, operating margin expansion from 8.8% to 15.6%, and ROE improvement to 48.8% demonstrate strong operational efficiency, cost control and profitability momentum. - Zero Liquid Discharge (ZLD) Facility
ZLD capability enhances sustainability, reduces environmental risk, and differentiates the company from peers, supporting regulatory compliance and customer acceptance in international markets. - Strong Customer Stickiness
With over 90% repeat business, the company has deep relationships and high product dependency within client operations, ensuring long-term order continuity and stable revenue streams.
Neochem Bio Solutions Limited Financial Information (Restated Consolidated)
Amount in (₹ in Lakhs)
| Period Ended | Sep 30, 2025 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Reserve of Surplus | 1,970.46 | 1,307.77 | 532.71 | 262.54 |
| Total Assets | 9,648.74 | 7,889.13 | 6,405.53 | 5,060.33 |
| Total Borrowings | 3,853.71 | 3,562.44 | 3,332.34 | 2,623.70 |
| Fixed Assets | 2,032.76 | 1,865.33 | 1,878.93 | 1,465.39 |
| Cash | 123.01 | 5.50 | 35.11 | 4.83 |
| Cash flow from operating activities | -768.92 | 259.47 | 196.42 | -74.18 |
| Cash flows from investing activities | 93.40 | -168.67 | -785.84 | -335.08 |
| Cash flow from financing activities | 793.04 | -120.41 | 619.91 | 357.71 |
| Net Borrowing | 3,730.70 | 3,556.94 | 3,297.23 | 2,618.87 |
| Revenue | 4,718.16 | 8,615.35 | 6,200.75 | 4,879.03 |
| EBITDA | 859.22 | 1,311.29 | 599.01 | 422.84 |
| PAT | 548.38 | 775.06 | 180.13 | 107.29 |
| PAT Margin | 11.62% | 9.00% | 2.90% | 2.20% |
| EPS | 4.52 | 6.64 | 1.9 | 2.03 |
Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2025 Data, given in RHP.
Note 3:- RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 4:- Price to Book Value calculation in KPI is based on Cap Price Post Issue Data, given in FINANCIAL EXPRESS.
Key Performance Indicator
| KPI | Values |
|---|---|
| EPS Pre IPO (Rs.) | 6.64 |
| EPS Post IPO (Rs.) | 4.53 |
| Adjusted 12M EPS Post IPO (Rs.) | 6.41 |
| P/E Pre IPO | 14.76 |
| P/E Post IPO | 21.65 |
| Adjusted 12M P/E Post IPO | 15.30 |
| ROE | 48.82% |
| ROCE | 41.67% |
| P/BV | 5.80 |
| Debt/Equity | 1.8 |
| RoNW | 48.82% |
| EBITDA Margin | 15.58% |
| PAT Margin | 9.00% |
Neochem Bio Solutions Limited IPO Peer Comparison
| Company Name | EPS | P/E (x) | ROE | ROCE | P/BV | Debt/Equity | RoNW (%) |
|---|---|---|---|---|---|---|---|
| Neochem Bio Solutions | 4.53 | 21.65 | 48.82% | 41.67% | 5.80 | 1.8 | 48.82% |
| Rossari Biotech | 24.66 | 26.00 | 12.2 % | 15.8 % | 2.64 | 0.28 | 5.78% |
| Indian Emulsifiers | 11.40 | 8.83 | 24.1 % | 23.6 % | 2.04 | 0.35 | 11.78% |
Neochem Bio Solutions Limited Contact Details
Neochem Bio Solutions Ltd.
303,
W1, Opp. Vikramnagar Colony,
Off. Iscon- Ambli Road,
Ahmedabad, Gujarat, 380058
Phone: +91 079 35217792
Email: compliance@neochem.in
Website: http://www.neochem.in/
Neochem Bio Solutions IPO Registrar and Lead Manager(s)
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: neochem.smeipo@in.mpms.mufg.com
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Vivro Financial Services Private Limited
Phone: +91-79-4040 4242
Email: investors@vivro.net
Website: www.vivro.net
Neochem Bio Solutions IPO Review
Neochem Bio Solutions Limited is a specialty performance chemicals manufacturer offering 350+ customized formulations across polymers, surfactants, silicones, esters and bio-based sustainable solutions. The company earns revenue by supplying customized chemicals to textile, home & personal care, industrial cleaning, paper, paints, water treatment and construction industries. Its products serve as critical functional additives improving strength, finishing, processing efficiency and lifecycle performance of end-use products.
The Company is led by Promoter, i.e., SWAPNIL RAMESHBHAI MAKATI AND HEMANGINI SWAPNIL DATHIA
The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹
4,718.16 Lakh, ₹
8,615.35 Lakh, ₹
6,200.75 Lakh, and ₹
4,879.03 Lakh, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹859.22 Lakh, ₹
1,311.29 Lakh, ₹
599.01 Lakh, and ₹
422.84 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹
548.38 Lakh, ₹
775.06Lakh, ₹
180.13 Lakh, and ₹
107.29 Lakh, respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹6.64 and post-issue EPS of ₹4.53 for FY25. The pre-issue P/E ratio is 14.76x,while the post-issue P/E ratio is 21.65x against the Industry P/E ratio is 17.42x The company's ROE for FY25 is 48.82% and RoNW is 48.82% The Annualised EPS is ₹6.41x and P/E is
15.30x. These metrics suggest that the IPO is Fully priced.
The Grey Market Premium (GMP) of Neochem Bio Solutions showing listing gains of
0%.Given the company's financial performance and the valuation of the IPO, we recommend Investors to Avoid to the Neochem Bio Solutions Limited IPO for Listing gain or Long Term Purposes.
Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. We also use Artificial Intelligence (AI) tools to enhance the efficiency and quality of our research services, including data retrieval, analysis, and report summarization. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit Legal our website abhayvarn.com
About the Author
CA Abhay Kumar (Also known as CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.





